{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-275867","form_type":"8-K","ticker":"ARTV","cik":"0001817241","company_name":"Artiva Biotherapeutics, Inc.","filed_at":"2025-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.573300+00:00","generated_at":"2026-05-16T21:25:43.666953+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Artiva Q3 net loss $21.5M; AlloNK gets FDA Fast Track for RA","bullets":["Over 100 patients dosed with AlloNK; FDA Fast Track Designation for refractory RA with rituximab.","Initial response data for >15 refractory RA patients expected 1H 2026; FDA discussions planned.","Cash, equivalents, investments $123M as of Sep 30, 2025; runway into Q2 2027.","Q3 R&D expense $17.6M, G&A $5.3M; net loss $21.5M vs $17.5M year ago.","CFO Neha Krishnamohan to step down end of Dec, advisory role; successor search underway."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-275867","json":"https://secwatch.observer/filing/0001193125-25-275867.json","markdown":"https://secwatch.observer/filing/0001193125-25-275867.md","text":"https://secwatch.observer/filing/0001193125-25-275867.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1817241/000119312525275867/0001193125-25-275867-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1817241/000119312525275867/artv-20251112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T21:25:43.666953+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}